Jairath V, Danese S, D'Haens GR, Feagan BG, et al. Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial. Lancet Gastroenterol Hepatol 2025 Nov 13:S2468-1253(25)00296.
PMID: 41242336